Galaxy Biomedical Investment Co., Ltd. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was CNY 160.729 million compared to CNY 188.083 million a year ago. Operating loss was CNY 11.907 million compared to CNY 19.692 million a year ago. Net loss was CNY 12.415 million compared to CNY 20.482 million a year ago. Basic loss per share from continuing operations was CNY 0.0113 compared to CNY 0.0186 a year ago.